Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging (2017) 0.78

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. Oncotarget (2016) 0.77

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. Ann Transl Med (2017) 0.75

The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer. PLoS One (2017) 0.75

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94

Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85

Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol (1998) 11.84

Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02

First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst (2005) 9.10

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (1991) 8.68

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA (2014) 6.32

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10

MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 5.06

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res (2008) 4.30

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res (2005) 4.13

Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A (1987) 3.99

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol (2009) 3.57

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res (2003) 3.39

Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol (2008) 3.23

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature (2011) 3.18

Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res (2006) 3.12

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol (2014) 3.01

Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01

The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature (2002) 2.99

Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A (1997) 2.92

c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev (2003) 2.81

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72

Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol (2001) 2.72

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol (2011) 2.69

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61

Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene (2000) 2.52

Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem (2000) 2.47

Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A (1994) 2.36

A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene (2000) 2.35

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene (2000) 2.27

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19

Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun (1992) 2.11

Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A (2001) 2.08

Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06

Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res (2009) 2.01

c-Met is essential for wound healing in the skin. J Cell Biol (2007) 1.98

Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest (2000) 1.90

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A (2003) 1.90

Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res (2003) 1.85

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol (2009) 1.81

Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer (1998) 1.75

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol (2008) 1.74

The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer (2004) 1.71

Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J (1992) 1.68

Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer (1999) 1.68

EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. Int J Cancer (2008) 1.55

The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev (2013) 1.54

Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene (2002) 1.53

Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol (1999) 1.52

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer (2009) 1.48

Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res (2005) 1.47

Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene (2004) 1.43

The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature (2005) 1.37

Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer (1996) 1.35

Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer (2003) 1.34

Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res (2002) 1.26

Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer (2009) 1.23

Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem J (2010) 1.20

Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int (2001) 1.20

Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res (2009) 1.19

Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem Biophys Res Commun (2010) 1.19

Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol (2002) 1.18

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol (2015) 1.17

Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol (2012) 1.15

Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer (2009) 1.11

Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res (2006) 1.10

Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol (2009) 1.10

Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol (2012) 1.08

Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol (2010) 1.08

Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell (2009) 1.06

PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest (2009) 1.04

FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis (2012) 1.01

HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer (2011) 1.00

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res (2014) 0.99

Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol (2013) 0.98

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. Br J Cancer (2014) 0.97

Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol (2006) 0.96

MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy. Cancer (2013) 0.96

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience (2013) 0.95

Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg Oncol (1996) 0.94

Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer (2014) 0.92

Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment. J Thorac Oncol (2011) 0.90

A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res (2013) 0.88

Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. Int J Urol (1998) 0.88

Prognostic role of c-met expression in breast cancer patients. Rep Pract Oncol Radiother (2011) 0.87

A novel germline mutation in the MET extracellular domain in a Korean patient with the diffuse type of familial gastric cancer. J Med Genet (2003) 0.86